Bone Biologics Corp Warrants
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more
Bone Biologics Corp Warrants (BBLGW) - Total Liabilities
Latest total liabilities as of June 2025: $406.14K USD
Based on the latest financial reports, Bone Biologics Corp Warrants (BBLGW) has total liabilities worth $406.14K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bone Biologics Corp Warrants - Total Liabilities Trend (2012–2024)
This chart illustrates how Bone Biologics Corp Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bone Biologics Corp Warrants Competitors by Total Liabilities
The table below lists competitors of Bone Biologics Corp Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bastas Baskent Cimento Sanayi ve Ticaret AS
IS:BASCM
|
Turkey | TL230.05 Million |
|
Foodlink A.E
AT:FOODL
|
Greece | €48.09 Million |
|
Urbanise.com Ltd
AU:UBN
|
Australia | AU$12.05 Million |
|
Elon AB (publ)
ST:ELON
|
Sweden | Skr1.53 Billion |
|
UTStarcom Holdings Corp
NASDAQ:UTSI
|
USA | $20.69 Million |
|
Transcode Therapeutics Inc
NASDAQ:RNAZ
|
USA | $3.80 Billion |
|
Digital Graphics Incorporation
KQ:043360
|
Korea | ₩4.44 Billion |
|
Seamless Distribution Systems AB
ST:SDS
|
Sweden | Skr339.60 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Bone Biologics Corp Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bone Biologics Corp Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bone Biologics Corp Warrants (2012–2024)
The table below shows the annual total liabilities of Bone Biologics Corp Warrants from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $377.71K | -54.57% |
| 2023-12-31 | $831.40K | -67.37% |
| 2022-12-31 | $2.55 Million | +2450.25% |
| 2021-12-31 | $99.91K | -99.27% |
| 2020-12-31 | $13.69 Million | +15.08% |
| 2019-12-31 | $11.90 Million | +23.44% |
| 2018-12-31 | $9.64 Million | +4.87% |
| 2017-12-31 | $9.19 Million | -4.33% |
| 2016-12-31 | $9.61 Million | +23.78% |
| 2015-12-31 | $7.76 Million | +3.21% |
| 2014-12-31 | $7.52 Million | +32.03% |
| 2013-12-31 | $5.70 Million | +121648.85% |
| 2012-12-31 | $4.68K | -- |